Soligenix - U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma

15 Views
administrator
administrator
08/09/23

Soligenix Investor Webcast Event held on Tuesday, January 26, 2021 from 2:30-4:00 PM Eastern Standard Time (EST) regarding United States (U.S) commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next